During the past decade, Vanderbilt Heart and Vascular Institute conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 13 clinical trials were completed, i.e. on average, 118.2% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vanderbilt Heart and Vascular Institute" #1 sponsor was "Abbott Medical Devices" with 7 trials, followed by "Pfizer" with 3 trials sponsored, "AtriCure, Inc." with 2 trials sponsored, "Biosense Webster, Inc." with 1 trials sponsored and "Cardiovascular Center Frankfurt" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vanderbilt Heart and Vascular Institute" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Vanderbilt Heart and Vascular Institute" are "Atrial Fibrillation" (4 trials), "Heart Failure" (3 trials), "Stroke" (3 trials), "Bleeding" (2 trials) and "Ventricular Tachycardia" (2 trials). Many other conditions were trialed in "Vanderbilt Heart and Vascular Institute" in a lesser frequency.

Most popular intervention types in "Vanderbilt Heart and Vascular Institute" are "Device" (13 trials), "Drug" (9 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "99mTechnicium (sestamibi or tetrofosmin)" (1 trials), "Ablation procedure staged catheter ablation" (1 trials), "Amplatzer Duct Occluder" (1 trials) and "Amulet Left Atrial Appendage Occluder" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vanderbilt Heart and Vascular Institute" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Vanderbilt Heart and Vascular Institute". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Vanderbilt Heart and Vascular Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Vanderbilt Heart and Vascular Institute, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 9 trials that are defined as “Not Applicable".